Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives $37.20 Average Target Price from Brokerages

Enliven Therapeutics, Inc. (NASDAQ:ELVN) has earned an average recommendation of “Buy” from the five research firms that are presently covering the company, MarketBeat.com reports. Five equities research analysts have rated the stock with a buy recommendation. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $39.60.

A number of research firms recently commented on ELVN. HC Wainwright increased their price objective on Enliven Therapeutics from $39.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, May 15th. Robert W. Baird increased their price objective on Enliven Therapeutics from $40.00 to $52.00 and gave the stock an “outperform” rating in a report on Monday. The Goldman Sachs Group began coverage on Enliven Therapeutics in a report on Monday. They issued a “buy” rating and a $37.00 price objective on the stock. Finally, Jones Trading dropped their price objective on Enliven Therapeutics from $36.00 to $27.00 and set a “buy” rating on the stock in a report on Friday, May 16th.

Enliven Therapeutics Price Performance

Shares of ELVN opened at $21.57 on Monday. The company has a market capitalization of $1.06 billion, a price-to-earnings ratio of -11.23 and a beta of 0.79. Enliven Therapeutics has a fifty-two week low of $13.30 and a fifty-two week high of $30.03. The business’s 50-day moving average is $18.55 and its 200-day moving average is $20.60.

Enliven Therapeutics (NASDAQ:ELVN) last issued its earnings results on Wednesday, May 14th. The company reported ($0.57) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.06). Equities research analysts expect that Enliven Therapeutics will post -1.95 earnings per share for the current fiscal year.

Insider Buying and Selling at Enliven Therapeutics

In other Enliven Therapeutics news, CFO Benjamin Hohl sold 3,250 shares of the stock in a transaction that occurred on Thursday, March 27th. The stock was sold at an average price of $21.33, for a total transaction of $69,322.50. Following the transaction, the chief financial officer now owns 23,000 shares in the company, valued at $490,590. This trade represents a 12.38% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Joseph P. Lyssikatos sold 5,000 shares of the stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $16.07, for a total value of $80,350.00. Following the transaction, the insider now owns 997,688 shares in the company, valued at approximately $16,032,846.16. This trade represents a 0.50% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 88,611 shares of company stock worth $1,695,914 over the last 90 days. Insiders own 25.90% of the company’s stock.

Institutional Investors Weigh In On Enliven Therapeutics

Several hedge funds have recently modified their holdings of ELVN. Charles Schwab Investment Management Inc. boosted its position in shares of Enliven Therapeutics by 2.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 261,888 shares of the company’s stock valued at $5,892,000 after acquiring an additional 6,611 shares during the period. Swiss National Bank lifted its position in Enliven Therapeutics by 13.9% in the fourth quarter. Swiss National Bank now owns 41,873 shares of the company’s stock worth $942,000 after purchasing an additional 5,100 shares during the period. Intech Investment Management LLC bought a new position in Enliven Therapeutics in the fourth quarter worth $367,000. KLP Kapitalforvaltning AS bought a new position in Enliven Therapeutics in the fourth quarter worth $97,000. Finally, Vanguard Group Inc. lifted its position in Enliven Therapeutics by 2.9% in the fourth quarter. Vanguard Group Inc. now owns 1,975,655 shares of the company’s stock worth $44,452,000 after purchasing an additional 55,283 shares during the period. 95.08% of the stock is owned by institutional investors.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.